Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Total Liabilities (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Total Liabilities data on record, last reported at $21.3 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 2.5% year-over-year to $21.3 million; the TTM value through Sep 2025 reached $21.3 million, up 2.5%, while the annual FY2024 figure was $23.3 million, 52.32% down from the prior year.
  • Total Liabilities reached $21.3 million in Q3 2025 per TNXP's latest filing, up from $19.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $48.9 million in Q4 2023 and bottomed at $12.5 million in Q1 2025.
  • Average Total Liabilities over 3 years is $23.0 million, with a median of $20.8 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: skyrocketed 99.11% in 2024, then crashed 54.14% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $48.9 million in 2023, then plummeted by 52.32% to $23.3 million in 2024, then fell by 8.72% to $21.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $21.3 million in Q3 2025, $19.4 million in Q2 2025, and $12.5 million in Q1 2025.